Clinical and Experimental Nephrology

, Volume 15, Issue 4, pp 560–566

Risk factors for metabolic syndrome in stable Italian renal transplant patients

Authors

    • Department of Clinical and Experimental MedicineUniversity Hospital “St. Anna”, University of Ferrara
  • Maurizio Bergami
    • Renal UnitUniversity Hospital “St. Anna”
  • Christian Molino
    • Department of Clinical and Experimental MedicineUniversity Hospital “St. Anna”, University of Ferrara
  • Alfredo De Giorgi
    • Department of Clinical and Experimental MedicineUniversity Hospital “St. Anna”, University of Ferrara
  • Marco Pala
    • Department of Clinical and Experimental MedicineUniversity Hospital “St. Anna”, University of Ferrara
  • Carlo Longhini
    • Department of Clinical and Experimental MedicineUniversity Hospital “St. Anna”, University of Ferrara
  • Francesco Portaluppi
    • Department of Clinical and Experimental MedicineUniversity Hospital “St. Anna”, University of Ferrara
    • Hypertension CenterUniversity Hospital “St. Anna”
Original Article

DOI: 10.1007/s10157-011-0422-4

Cite this article as:
Fabbian, F., Bergami, M., Molino, C. et al. Clin Exp Nephrol (2011) 15: 560. doi:10.1007/s10157-011-0422-4

Abstract

Background

The prevalence of metabolic syndrome (MS) in renal transplant recipients (RTR) is still under investigation.

Methods

We performed a cross-sectional study of 107 stable RTR who were diagnosed as having MS defined by the Adult Treatment Panel III of the National Cholesterol Education Program (NCEP-ATP III) criteria. Anthropometric, clinical and biochemical data were collected.

Results

Mean age of the patients studied was 55 ± 11 years (72 male, 35 female), dialysis duration before transplantation 30 ± 31 months, time since transplantation 42 ± 13 months. Mean serum creatinine was 1.68 ± 0.64 mg/dl; creatinine clearance by Cockcroft–Gault formula 53 ± 20 ml/min, glomerular filtration rate by 4-variable MDRD formula 48 ± 18 ml/min/1.73 m2. Thirty-seven patients (34.5%) had MS. The MS patients had higher weight (76 ± 13 vs. 68 ± 12 kg, p = 0.0033), body mass index (BMI) (26 ± 4 vs. 24 ± 3 kg/m2, p = 0.0025), waist circumference (101 ± 11 vs. 90 ± 11 cm, p < 0.0001), prevalence of BMI >25 k/m2 (57 vs. 34%, p = 0.0254), prevalence of diabetes mellitus before transplantation (8 vs. 0%, p = 0.0157), glycaemia (104 ± 31 vs. 87 ± 11 mg/dl, p = 0.0002), and triglyceridaemia (225 ± 105 vs. 112 ± 35 mg/dl, p < 0.0001). They also showed lower levels of high-density lipoprotein cholesterol (48 ± 15 vs. 68 ± 17 mg/dl, p < 0.0001). Multiple logistic regression analysis showed that only BMI was independently associated with MS (OR 1.21, 95% CI 1.06–1.37, p = 0.0037).

Conclusions

MS according to NCEP-ATP III criteria appears to be present in about one-third of RTR, and even small increases in BMI above 25 kg/m2 may determine the presence of MS in these patients. Therefore the preventive value of lifestyle modifications is very important for such patients, in order to strictly maintain body fat accumulation within the normal range.

Keywords

Metabolic syndrome Body mass index Renal transplant recipients Renal graft function

Copyright information

© Japanese Society of Nephrology 2011